Angiogenic tumor markers, antiangiogenic agents and radiation therapy.
There are many exciting avenues to pursue in angiogenesis-related cancer research. Until now, conventional therapy has targeted neoplastic cells within a tumor. However, tumor vasculature is emerging as a new cancer target. Antiangiogenic drugs are unique in having highly specific targets, while simultaneously carrying the potential to be effective against a wide breadth of cancer types. They also act synergistically with cytotoxic therapy. Currently, this combination of new antiangiogenic treatments with traditional cytotoxic treatments such as radiotherapy, may provide a powerful means of combating cancer. Strategic combination therapy, selecting for tumor type and angiogenic profile, may result in the realization of the promise and potential of antiangiogenic therapy.
Chan
Linda W
LW
Imaging and Molecular Therapeutics Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda MD, USA. linda_chan@student.hms.harvard.edu
Camphausen
Kevin
K
D043925:Angiogenesis Inducing Agents / Q000378:metabolism*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor